Evidence-based·Last reviewed May 30, 2026·How we grade evidence

Acetyl L-Carnitine

Amino-acidCarnitine derivative

Useful mainly for adults with diabetic peripheral neuropathy or age-related cognitive fatigue seeking mitochondrial and cholinergic support.

Quick decision guide

May help most

Adults with diabetic peripheral neuropathy or age-related cognitive fatigue seeking mitochondrial and cholinergic support

Common dosing range

1–2 g/day split into 2 doses

When to expect effects

Weeks (neuropathy symptoms); weeks to months (cognitive effects)

Watch out for

Avoid with bipolar disorder (risk of mania induction); coordinate with neurologist if on Alzheimer's cholinesterase inhibitors; mildly stimulating — avoid late-day dosing

What is it

Acetyl-L-carnitine (ALCAR) is an acetylated form of L-carnitine, an amino-acid-derived compound the body synthesizes from lysine and methionine in the liver, kidneys, and brain. The added acetyl group helps it cross the blood-brain barrier, making it the preferred form for cognitive and neurological applications.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You have diabetic peripheral neuropathy and want an adjunct with reasonable evidence
You are an older adult with fatigue and are looking for mitochondrial support with CNS access
You are exploring adjuncts for mild cognitive impairment under neurologist guidance

Probably skip if…

You have bipolar disorder (mania risk)
You have a seizure disorder without neurologist clearance
You take donepezil, rivastigmine, or other cholinesterase inhibitors without specialist coordination
You expect significant cognitive improvement beyond what trials have shown in early-stage disease

Evidence at a glance

diabetic peripheral neuropathy

Good Evidence
Effect
Moderate reduction in neuropathic pain and improved nerve conduction in RCTs
Best fit
Adults with type 2 diabetes and established peripheral neuropathy
Time
4–12 weeks

mild cognitive impairment and early Alzheimer's disease

Limited Evidence
Effect
Small slowing of cognitive decline in some trials; inconsistent across studies
Best fit
Older adults with mild cognitive impairment or very early Alzheimer's disease
Time
3–6 months

depressive symptoms

Limited Evidence
Effect
Modest symptom reduction in small RCTs; more notable in older adults with dysthymia
Best fit
Older adults with mild-to-moderate depression or dysthymia
Time
4–8 weeks

fatigue in older adults

Limited Evidence
Effect
Modest improvements in fatigue and physical function in elderly trial populations
Best fit
Older adults with fatigue associated with sarcopenia or chronic illness
Time
4–8 weeks

Evidence for 4 uses

AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.

diabetic peripheral neuropathy

Disease adjunct
Good Evidence

Multiple RCTs using 2 g/day ALCAR in diabetic neuropathy show significant reductions in neuropathic pain scores and improvements in nerve conduction velocity compared to placebo over 6–12 months. A meta-analysis supports meaningful pain reduction. Mechanism involves nerve mitochondrial support and regenerative effects on axonal structure. Evidence quality is moderate.

Effect size
Moderate reduction in neuropathic pain and improved nerve conduction in RCTs
Time to effect
4–12 weeks
Best fit
Adults with type 2 diabetes and established peripheral neuropathy
Less likely
People without diabetes or with neuropathy from non-metabolic causes

Bottom line: The strongest indication for ALCAR; reasonably well-supported as an adjunct for diabetic peripheral neuropathy.

SourceRolim et al., 2019 — PMCLi et al., 2016 — PMC

mild cognitive impairment and early Alzheimer's disease

Disease adjunct
Limited Evidence

A systematic review of RCTs showed a statistically significant but clinically modest benefit on cognitive scores in early Alzheimer's and age-related cognitive decline. Results are inconsistent across trials — some show benefit, others do not. ALCAR's cholinergic and mitochondrial mechanisms are plausible but have not translated to consistent clinical benefit at the level seen with pharmaceutical cholinesterase inhibitors.

Effect size
Small slowing of cognitive decline in some trials; inconsistent across studies
Time to effect
3–6 months
Best fit
Older adults with mild cognitive impairment or very early Alzheimer's disease
Less likely
Healthy younger adults; people with moderate-to-severe Alzheimer's

Bottom line: Modest and inconsistent cognitive benefit in early Alzheimer's; not equivalent to pharmaceutical treatment.

Evidence is mixed

Individual trial results are mixed; a meta-analysis suggests a modest positive signal, but effect size confidence intervals are wide and some trials are negative.

SourceMontgomery et al., 2003 — PubMed· conflictingSpagnoli et al., 1991 — PubMed· conflicting
SourceMontgomery et al., 2003 — PubMedSpagnoli et al., 1991 — PubMed

depressive symptoms

Disease adjunct
Limited Evidence

Several small RCTs show ALCAR (1–3 g/day) reduces depressive symptom scores compared to placebo, with the most consistent findings in older adults with dysthymia. A meta-analysis reports significant pooled effects, but trial quality is variable and sample sizes are small. ALCAR is not a replacement for antidepressant pharmacotherapy.

Effect size
Modest symptom reduction in small RCTs; more notable in older adults with dysthymia
Time to effect
4–8 weeks
Best fit
Older adults with mild-to-moderate depression or dysthymia
Less likely
Younger adults with major depression; people on established antidepressant therapy

Bottom line: Preliminary evidence for mild depression in older adults; should not replace established antidepressant treatment.

SourceVeronese et al., 2018 — PubMedBrennan et al., 2013 — PMC

fatigue in older adults

Supplement benefit
Limited Evidence

Small RCTs in frail or chronically ill older adults show ALCAR (1.5–2 g/day) modestly improves fatigue, physical performance, and mental performance scores. The mechanism involves improved mitochondrial fatty acid metabolism supporting muscle and brain energy. Evidence is limited to short trials in selected populations.

Effect size
Modest improvements in fatigue and physical function in elderly trial populations
Time to effect
4–8 weeks
Best fit
Older adults with fatigue associated with sarcopenia or chronic illness
Less likely
Healthy young adults with fatigue from other causes

Bottom line: Modest fatigue benefit in elderly or frail populations; limited data in other groups.

SourceMalaguarnera et al., 2011 — PubMedMalaguarnera et al., 2008 — PubMed

How it works

Like L-carnitine, ALCAR helps transport long-chain fatty acids into mitochondria for oxidation, supporting ATP production in tissues that depend heavily on fat metabolism (heart, skeletal muscle, brain). The acetyl group is its real distinguishing feature: once across the blood-brain barrier, ALCAR donates that acetyl group for the synthesis of acetylcholine, the neurotransmitter critical to memory, attention, and cholinergic neuron function. ALCAR also helps remove toxic compounds from mitochondria and supports mitochondrial biogenesis, which is the basis for its neuroprotective hypothesis in Alzheimer's disease and age-related cognitive decline. Cholinergic neurons degenerate in Alzheimer's, and ALCAR may support both acetylcholine production and mitochondrial resilience in those vulnerable cells. Bioavailability of ALCAR specifically has not been thoroughly characterized, but it is generally assumed to be similar to or somewhat better than free L-carnitine's 14 to 18 percent oral absorption, with the added advantage of better central nervous system penetration.

How to take it

1. Typical dose
1–2 g/day for most indications; up to 3 g/day in some neuropathy and cognitive trials
2. Higher studied dose
3 g/day used in some Alzheimer's and depression trials
3. Timing
Morning and early afternoon (e.g., 500–1,000 mg at breakfast, 500–1,000 mg at lunch); avoid within 6 hours of bedtime
4. With food
Empty stomach 20–30 minutes before meals for slightly better absorption; acceptable with food if GI upset occurs
5. Split dosing
Always split into at least 2 daily doses for steady plasma levels
6. How long to try
4–8 weeks minimum for neuropathy assessment; 3 months for cognitive outcomes

What to track

Peripheral neuropathy symptom score (pain, tingling, numbness)
Fatigue rating and subjective energy
Sleep quality (note if late dosing disrupts sleep)
Mood (monitor for hypomanic symptoms in anyone with mood history)

3 commercial forms

Compare the main delivery options and what they’re best suited for.

Acetyl-L-carnitine HCl

The most common consumer form, typically in 500 mg or 1,000 mg capsules. Slightly hygroscopic, so look for moisture-resistant packaging.

Crosses the blood-brain barrier; the standard form used in cognitive and neuropathy trials.

Acetyl-L-carnitine arginate

Marketed as enhancing circulation and absorption. Few independent trials confirm a clinical advantage over plain ALCAR.

ALCAR combined with arginine; theoretical advantages around nitric oxide and vasodilation, but limited direct evidence.

ALCAR + alpha-lipoic acid stack

Often paired in anti-aging and cognitive protocols based on rodent work suggesting synergy on mitochondrial biogenesis. Human evidence for the synergy is thinner than the marketing suggests.

No direct absorption conflict; combination targets mitochondrial function.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

mild nauseaGI upsetrestlessnessinsomnia if taken late in the dayfishy body odor at high doses

Serious risks

  • Mania induction in bipolar disorder (case reports)

  • Possible increased seizure risk in seizure disorders

Who should avoid it

  • People with bipolar disorder
  • People with active seizure disorders without neurologist clearance
  • People with chronic kidney disease (carnitine handling is impaired)
  • People on cholinesterase inhibitors for Alzheimer's without neurologist coordination

Pregnancy & breastfeeding

Insufficient safety data for supplemental ALCAR in pregnancy; avoid without clinician guidance.

Interactions

cholinesterase inhibitors (donepezil, rivastigmine, galantamine)Moderate

ALCAR raises acetylcholine; additive cholinergic effects could increase side effects; requires neurologist coordination

anticonvulsants (valproate, phenobarbital, phenytoin, carbamazepine)Moderate

These drugs deplete carnitine; ALCAR may partially offset depletion but interaction effects require monitoring

thyroid hormone medicationsMinor

Case reports of reduced thyroid hormone efficacy; monitor thyroid function if combining

warfarinMinor

Carnitine supplementation has been associated with altered INR in case reports; monitor if combining

Food sources

Beef steak (3 oz, cooked)

Amount
42 to 122 mg carnitine
%DV
—

Ground beef (3 oz, cooked)

Amount
65 to 74 mg carnitine
%DV
—

Whole milk (1 cup)

Amount
8 mg carnitine
%DV
—

Cod (3 oz, cooked)

Amount
3 to 5 mg carnitine
%DV
—

Chicken breast (3 oz, cooked)

Amount
2 to 4 mg carnitine
%DV
—

Cheddar cheese (2 oz)

Amount
2 mg carnitine
%DV
—

Choosing a product

What to look for on the label — and what to be skeptical of.

Look for…

Acetyl-L-carnitine specifically labeled (not L-carnitine or L-carnitine tartrate, which do not cross the blood-brain barrier as effectively)
Dose per capsule clearly stated in mg
Third-party tested for identity and purity

Be skeptical of…

Cures Alzheimer's disease or reverses dementia
Interchangeable with L-carnitine for brain health — the acetyl group is essential for CNS activity
Burns fat or enhances athletic performance as a primary use (evidence much weaker than for neuropathy)
Safe for bipolar disorder

Frequently asked questions

What's the difference between L-carnitine and acetyl-L-carnitine?⌄

Both come from the same compound family. L-carnitine acts mainly in heart and skeletal muscle to shuttle fats into mitochondria. Acetyl-L-carnitine (ALCAR) has an added acetyl group that lets it cross the blood-brain barrier, where it supports acetylcholine production and brain mitochondrial function. ALCAR is preferred for cognitive and neuropathy applications; L-carnitine for cardiovascular and muscular ones.

Does ALCAR really help with focus and memory?⌄

In adults with mild cognitive impairment or early Alzheimer's, 1.5 to 3 g/day showed modest cognitive improvements in older meta-analyses, but later, longer trials were less impressive. In healthy young adults, evidence for nootropic effects is limited and largely anecdotal.

When should I take ALCAR?⌄

Most people take it on an empty stomach in the morning and again at midday. It has a mild alerting effect, so taking it late in the day can disrupt sleep for some users.

Is ALCAR safe long-term?⌄

Trials up to 12 months at 1.5 to 3 g/day have been well tolerated. Long-term data beyond a year are limited. The TMAO concern raised about L-carnitine cardiovascular risk likely applies to ALCAR as well, though less directly studied.

Can I take ALCAR with my Alzheimer's medication?⌄

Coordinate with the prescribing neurologist. ALCAR raises acetylcholine, which is what cholinesterase inhibitors (Aricept, Exelon, Razadyne) also do via a different mechanism. The interaction is not well characterized; do not combine without medical guidance.

Will ALCAR help with energy or workout performance?⌄

Effects on athletic performance are mixed and generally less robust than for L-carnitine (which itself shows mixed results). ALCAR's stimulating quality may help with perceived energy but is unlikely to meaningfully change strength or endurance metrics.

References by claim

diabetic peripheral neuropathy

Rolim et al., 2019 — PMC (2019) link

Li et al., 2016 — PMC (2016) link

mild cognitive impairment and early Alzheimer's disease

Montgomery et al., 2003 — PubMed (2003) link

Spagnoli et al., 1991 — PubMed (1991) link

depressive symptoms

Veronese et al., 2018 — PubMed (2018) link

Brennan et al., 2013 — PMC (2013) link

fatigue in older adults

Malaguarnera et al., 2011 — PubMed (2011) link

Malaguarnera et al., 2008 — PubMed (2008) link

Track Acetyl L-Carnitine with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.

Coming to App Store
Evidence-based·Last reviewed May 30, 2026·Evidence current as of May 30, 2026·How we grade evidence

Disclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.